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Abstract
Background: Cervical cancer is the most common cancer in women in Ghana, but knowledge and experience of
women who have had cervical screening is under-evaluated. This study examined knowledge and understanding of
HPV and cervical cancer and evaluated experiences of screening in a cohort of women of mixed HIV status.
Methods: This was a mixed methods study using questionnaires and focus group discussions, with a knowledge
score constructed from the questionnaire. HIV-positive and HIV-negative women were recruited from a larger
cervical screening study in Ghana and were interviewed 6 months after receiving screening. Quantitative data was
analyzed and triangulated with qualitative data following thematic analysis using the framework approach.
Results: A total of 131 women were included (HIV-positive, n = 60). Over 80% of participants had a knowledge
score deemed adequate. There was no difference between HIV-status groups in overall knowledge scores (p = 0.1),
but variation was seen in individual knowledge items. HIV-positive women were more likely to correctly identify
HPV as being sexually-transmitted (p = 0.05), and HIV negative women to correctly identify the stages in developing
cervical cancer (p = < 0.0001).
HIV-positive women mostly described acquisition of HPV in stigmatising terms. The early asymptomatic phase of
cervical cancer made it difficult for women to define “what” cancer was versus “what” HPV infection was. All
women expressed that they found it difficult waiting for their screening results but that receiving information and
counselling from health workers alleviated anxiety.
Conclusions: Knowledge of women who had participated in a cervical screening study was good, but specific
misconceptions existed. HIV-positive women had similar levels of knowledge to HIV-negative, but different
misconceptions. Women expressed generally positive views about screening, but did experience distress. A
standardized education tool explaining cervical screening and relevance specifically of HPV-DNA results in Ghana
should be developed, taking into consideration the different needs of HIV-positive women.
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Background
Cervical cancer is responsible for the highest number of
cancer-related deaths among women in Ghana, with 3052
new cases and 1556 deaths annually [1]. HPV vaccines are
licenced for use, but have not been introduced beyond a
pilot program in selected regions commenced in 2013 [2].
Ghana has had a national policy on cervical cancer pre-
vention since 2005, which recommends screening with
visual inspection with acetic acid (VIA) and treatment of
lesions with cryotherapy for women between the ages of
25–45 years, and papanicolau (PAP) smears for women
over the age of 45 [3]. The National Screening Program so
far has limited coverage of estimated 2.7% of the eligible
population. Both Papanicolaou smears and VIA are avail-
able in public and private health clinics at a cost to the pa-
tient since the national health insurance does not cover it.
HIV infection is an established co-factor in the develop-
ment of cervical cancer as it increases susceptibility to per-
sistent HPV infection [4, 5]. Women living with HIV have
an incidence of cervical cancer seven times that of women
not infected with HIV, risk developing disease up to 10
years earlier, and require more frequent screening [4, 6].
Non-attendance at cervical screening remains a signifi-
cant problem in high-income countries with established
programmes, with an estimated 50–60% of cervical can-
cers occurring in women who have never attended screen-
ing [7, 8]. Poor knowledge about the disease and the
benefits of screening have been shown to be associated
with non-attendance [9, 10]. Barriers to women attending
screening include embarrassment related to sample collec-
tion, fear of pain, and fear of cancer diagnosis [11, 12].
Understanding the screening process and the benefits of
early treatment are fundamental to women engaging in
screening and follow-up care [10, 13]. This is especially im-
portant in low and middle-income countries (LMIC) where
costs and accessibility may represent significant barriers to
screening, as women are not incentivised to seek testing for
what is often an asymptomatic condition [14].
Surveys of women across Sub-Saharan Africa (SSA)
show great variation in women’s awareness and know-
ledge of cervical cancer [9, 15, 16]. A survey in
Ethiopia found that 78.7% of women surveyed had
heard of cervical cancer, but only 31% were deemed
“knowledgeable” [17]. In a study in the Democratic
Republic of Congo 81.9% of women surveyed had
heard of cervical cancer, but only 43% were felt to
have sufficient knowledge [18]. Surveys of market
women in Nigeria, and of women in health-facilities
in Kenya found only 6.9 and 29% of respondents, re-
spectively, having heard of cervical cancer [15, 19].
In Ghana there is also evidence of this variation, with
a survey of university students finding 93% of respon-
dents aware of cervical cancer in comparison to a survey
of women from the general population which found that
68.4% had never heard of cervical cancer, 93.6% were
not aware of the risk factors, and 97.7% had not heard of
cervical screening [9, 20].
Few studies in SSA have evaluated the knowledge of
women undergoing cervical cancer screening [21, 22],
but none has investigated the experience of women after
undergoing screening, and none have included women
living with HIV. The advent of HPV-DNA testing in
high-income countries has changed the experience of
cervical screening, with issues such as increased health-
anxiety, stigma of HPV infection, and confusion around
health information arising [23–25]. HPV-DNA testing is
now being used in conjunction with cytology in many
high-income countries, and has been adopted as the pri-
mary screening method in some [26, 27]. A number of
trials have evaluated the use of HPV-DNA testing in
low-resource environments, and have shown high sensi-
tivity for the detection of cervical intraepithelial neopla-
sia (CIN) grades 2 and above, in both human
immunodeficiency virus (HIV) seropositive and HIV-
negative women [28, 29]. Experience of HPV-DNA test-
ing has not yet been evaluated in Ghana or other SSA
countries as testing is not widely available. This area
needs exploration as low-cost rapid HPV DNA tests
suitable for use in the low resource setting have been de-
veloped and are expected to become more frequently
used for cervical screening [29].
This study examined the knowledge and understanding
of HPV, cervical cancer, and cervical cancer screening,
and evaluated the experience of cervical screening in a co-
hort of HIV-positive and HIV-negative women who had
received screening with a combination of cervical cytology
and HPV-DNA testing as part of another research study
[30–32]. The aim is to inform the development of effective
screening messages, improve information provided to
women around screening and evaluate whether women
living with HIV have different information needs.
Methods
Study design and population
We conducted a mixed-methods study using convergent
parallel design with quantitative and qualitative strands of
the study implemented concurrently, kept independent
during analysis and combined in interpretation [33]. We
used a combination of interviewer-administered question-
naires and focus group discussions (FGDs).
Participants were sampled purposively from a parent-
cohort study of women at the Cape Coast Teaching
Hospital (CCTH) in Cape Coast, Ghana, (parent study
N = 343, HIV-positive n = 173). The parent study was a
comparative-cohort study of HIV-positive and HIV-
negative women that investigated the epidemiology of
HPV and cervical squamous intraepithelial lesions (SIL);
evaluated a rapid HPV DNA screening test (careHPV,
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Qiagen, Gaithersburg, MD), and determined the per-
formance and acceptability of self-sampling for HPV
testing [30–32]. At parent-study enrolment, women
underwent gynaecological examination, HPV-DNA test-
ing and cervical cytology, and socio-demographic and
medical history data were collected. During this first
visit, they were also given basic facts about HPV and
cervical cancer. At 6-months participants were followed
up in clinic with review of symptoms, gynaecological
examination, and repeat cervical cytology. Women found
to have abnormal cytology after the first screening were
referred for gynaecological evaluation and treatment. At
the 6-month parent-study follow up visit participants
were informed about the sub-study and consenting indi-
viduals consecutively recruited.
There was no sample size calculation as the sub-study
was purely descriptive with no tested hypothesis. We
aimed to collect a minimum of 100 questionnaires (50%
HIV-positive). The inclusion criterion was participation
in the parent-study (age > 18 years and accepting HIV
testing); there were no exclusion criteria. Respondents
were asked on the questionnaire if they would consider
participating in a FGD; those who consented were called
at random until 16 (half of each HIV serostatus) had
been recruited.
Quantitative methods
A 32-item questionnaire was developed specifically for this
study through literature review and collaboration with the
parent-study investigators. Information on knowledge
(HPV, cervical cancer and screening) and screening expe-
riences of the women was gathered. The questionnaire
was piloted with administering study-personnel (four
nurses and one doctor) prior to initiation. The question-
naire was developed in English, but administered face-to-
face in the preferred language of the respondent. Clinic
staff were fluent in local languages and English and there
was no formal assessment of their language skills. Specific
translations of each question into local languages were
chosen during piloting. Demographic data, HPV and HIV
testing results were extracted from the parent-study.
Descriptive analysis using frequencies and percentages
with bivariate analysis by HIV-status and other participant
characteristics was performed on categorical data. Likert-
type item responses were grouped into “overall agree” “neu-
tral” and “overall disagree” from a five point response scale
of strongly disagree/disagree/neutral/agree/strongly agree.
Chi-square tests or Fisher’s exact test were used to obtain
p-values. A knowledge score was created from the know-
ledge items. Correct responses were scored as “1”, and in-
correct or “unsure” responses as “0”. There were nine
knowledge items in the questionnaire which participants
had been exposed to during parent-study counselling and
were defined as “expected” knowledge items. The parent
study counselling was delivered verbally through the clinic
nurses and doctor and was supplemented with an informa-
tion leaflet as part of the consent. The remaining ten know-
ledge items were not covered by parent-study counselling
and were thus not defined as “expected” areas of know-
ledge. Therefore, the cut-off for “adequate knowledge” was
a score of ≥9 (maximum score 19), which included correct
responses to any question, not just those that were defined
as “expected”. Bivariate analysis of mean knowledge score
by demographic variables was performed using t-tests and
ANOVA. Univariable risk factor analyses for knowledge ad-
equacy was performed and reported as odds ratios (ORs)
with 95% confidence interval (CI). Free-text responses were
presented descriptively. Data were analyzed using Stata13.1
(StataCorp, Texas, USA).
Qualitative methods
Focus-group discussions were held after the question-
naire collection phase had ended, and were run in the
School of Medical Sciences teaching building at CCTH.
There was no financial incentive for participation, but
light refreshments were served and costs of travel reim-
bursed. Participants were stratified into two FGDs by
HIV-status (eight participants in each). The aim of this
was to 1) reduce the risk of stigmatisation through inad-
vertent disclosure of HIV-status during discussions, and
2) examine differences/similarities in results. Participants
were not informed that their group was of particular
HIV-status, and were not aware of other members’ HPV
or cytology results.
A semi-structured topic guide using pre-scripted
open-ended questions was used, focusing on knowledge
and understanding of HPV, cervical cancer and screen-
ing; and on participants’ experience of the screening
process. Both FGDs were conducted in the local lan-
guage (Fante) and each lasted approximately 1h. Two fe-
male facilitators fluent in local languages and with
experience of conducting FGDs, were recruited from the
Institute of Development Studies at the University of
Cape Coast. FGDs were recorded onto digital audio re-
corders, and field notes recording interactions were
taken. Transcripts were translated into English and tran-
scribed verbatim, and checked for accuracy. Thematic
analysis was done using the Framework Method [34].
After familiarization with the transcripts, initial codes
were generated manually using an inductive approach.
Transcripts were then imported into Nvivo10 (QSR
International) and fully coded, with generation of add-
itional codes as they emerged. A framework matrix was
created, with themes and sub-themes generated from
the codes making up the columns of the matrix, and
cases (individual participants), the rows. Associations,
explanations and relationships were explored through
the framework.
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Results
Unless otherwise stated, numerical results in the text
are presented ordered as HIV-negative, HIV versus
positive. Findings from both quantitative and qualita-
tive aspects are presented together. A total of 135
women (HIV-positive, n = 60) completed the question-
naire, and 16 participated in the FGDs. Participant
characteristics by HIV-status are presented in Table 1.
Variables with significant differences by HIV-status
were distribution of ages between categories (p =
0.04), occupation (p < 0.0001), level of education (p <
0.001), relationship status (p < 0.001), cytology results
(p = 0.02), and HPV result (p = 0.001).
HPV and cervical cancer related knowledge
Results of the knowledge domains are presented in Table 2.
Questions with the highest proportion of correct responses
for HIV negative versus HIV positive women include HPV
being sexually transmitted (86.7100%), HPV being the cause
of cervical cancer (91.9% vrs. 98.2%), condoms being par-
tially protective (82.7% vrs. 94.6%), and cervical cancer be-
ing preventable (90.8% vrs. 94.6%). Questions with the
highest proportion of incorrect responses also tended to be
those with the highest proportions of “unsure” responses.
Questions showing difference by HIV-status included
whether HPV is sexually transmitted (p = 0.01) and whether
cervical cancer is rare in Ghana (p = 0.005), with HIV-
positive women giving more frequent correct answers.
HIV-negative women were more often correct in identify-
ing that cervical cancer has stages (p = < 0.001).
The symptoms that survey participants associated with
cervical cancer are detailed in Fig. 1. Postcoital bleeding,
offensive vaginal discharge and intermenstrual bleeding
were commonly correctly identified as potential symp-
toms (90.8, 90.1, and 70.1%). Pruritus was also a com-
monly misidentified as a potential symptom with 56.6%
of participants selecting it. Identifying that one could
still have cervical cancer but no symptoms was less com-
mon at 18.3%. More HIV-negative women (49.6% vrs.
40.5%, p = 0.04) correctly identified offensive vaginal dis-
charge as a symptom, but there were no other statisti-
cally significant differences between HIV-status groups.
The mean knowledge score for all survey participants
was 11.6 (SD + 2.7; range: 3–18), with no evidence of as-
sociation with HIV-status (p = 0.1). An “adequate” know-
ledge score (correct responses for ≥9 of 19 items) was
reached by 87.8% of participants, with no difference by
HIV-status (p = 0.11). On bivariate analysis having a
current partner was associated with having an adequate
knowledge score (OR 2.53, 95%CI 1.03–6.24, p = 0.04).
Four themes relating to women’s knowledge of HPV,
cervical cancer and screening were constructed from the
FGDs: “acquisition”, “nature of disease”, “protection” and
“testing”.
That HPV is sexually transmitted was commonly
expressed, and the majority of women were clear on this
with few incidences of misconceptions. The manner in
which participants described the acquisition of HPV was
categorised into “stigmatised” and “non-stigmatised”, with
“stigmatised” expressions putting a critical or “moral” judg-
ment on sexual transmission. These were more common
amongst HIV-positive women, and were mostly related to
the expression that sexual promiscuity was necessary for
acquisition of disease:
Table 1 Characteristics of 131 questionnaire participants
attending the Cape Coast Teaching Hospital, Ghana, by HIV-
status
HIV-negative
(n = 76) (%*)
HIV-positive
(n = 55)(%*)
p value
Mean age (SD), years 43.9 (11.4) 42.9 (8.4) 0.59**
Age, by category, years
20–29 6 (7.9) 2 (3.6) 0.04†
30–39 26 (34.2) 16 (29.1)
40–49 17 (22.4) 26 (47.3)
50–59 22 (29) 8 (14.6)
60–70 5 (6.6) 3 (5.5)
Occupation
Unemployed 4 (5.3) 3 (5.5) 0.000†
Unskilled work 38 (50.0) 48 (87.3)
Skilled work 34 (44.7) 4 (7.3)
Religion
Christian 69 (90.8) 47 (88.5) 0.39†
Muslim 7 (9.2) 7 (12.7)
Traditional 0 (0) 1 (1.8)
Relationship status
Current partner 58 (76.3) 26 (47.3) < 0.001‡
No current partner 18 (23.7) 29 (52.7)
Level of education
< 6 years formal education 11 (14.5) 29 (52.7) < 0.001‡
> 6 years formal education 65 (85.5) 26 (47.3)
Mean number of children 2.3 (1.9) 2.7 (1.8) 0.22**
HPV result
HPV positive 32 (42.1) 39 (70.9) 0.001‡
HPV negative 44 (57.9) 16 (29.1)
Cytology result
0.005
Positive (> = ASCUS) 1 (1.3) 6 (10.9) 0.02‡
Negative 75 (98.7) 49 (89.1)
ASCUS atypical squamous cells of undetermined significance, SD
standard deviation
* percentages may not sum to 100 due to rounding
** calculated using two sample t-test
† calculated using Fisher’s exact test
‡ calculated using Chi-squared test
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Table 2 Responses to questionnaire knowledge-items among
women (n = 131)
HIV-negative (%*)
N = 76
HIV-positive
(%*) N = 55
p value
HPV is sexually transmitted♦
True 86.7% 100.0% 0.01†
False 6.7% 0.0%
Unsure 6.7% 0.0%
HPV causes cervical cancer♦
True 91.9% 98.2% 0.2†
False 0.0% 0.0%
Unsure 8.1% 1.8%
HPV infection is rare:
not many people have it♦
True 20.0% 25.5% 0.06‡
False 41.3% 21.8%
Unsure 38.6% 52.7%
Cervical cancer is rare in Ghana♦
True 33.3% 21.8% 0.005‡
False 40.0% 23.6%
Unsure 26.7% 54.6%
If there are women in your family
(who are blood relatives) who have
had cervical cancer, this means it
is more likely to happen to you. ♦
True 66.7% 30.9% <
0.001†
False 6.7% 3.6%
Unsure 26.7% 65.5%
Which of these do you think
can be signs of cervical cancer?~
Bleeding after sex 15.9% 13.2% –
Smelly discharge
from the vagina
15.6% 13%
Bleeding in between
menstrual periods♦
12.7% 10.0%
Itching of the vagina 6.6% 7.1%
No symptoms♦ 3.7% 2.2%
Cervical cancer can be
prevented♦
True 90.8% 94.6%
False 1.3% 0% 0.8†
Unsure 7.9% 5.5%
Only women who are having
vaginal complaints should
have cervical screening♦
True 4.0% 3.6% 1.000†
False 94.7% 94.6%
Unsure 1.3% 1.8%
Men cannot be
infected with HPV
True 20.0% 25.5% 0.3†
Table 2 Responses to questionnaire knowledge-items among
women (n = 131) (Continued)
HIV-negative (%*)
N = 76
HIV-positive
(%*) N = 55
p value
False 66.6% 69.1%
Unsure 13.3% 5.5%
Condoms offer some
protection from getting
infected with HPV
True 82.7% 94.6% 0.1†
False 6.7% 3.6%
Unsure 10.7% 1.8%
Using herbs in the
vagina makes you
more likely to get
cervical cancer
True 36.8% 21.8% 0.03†
0.03†
False 7.9% 1.8%
Unsure 55.3% 76.4%
Having an abortion
or miscarriage makes
you more likely to
get cervical cancer
True 22.4% 21.8% 0.6†
False 13.2% 7.3%
Unsure 64.5% 70.9%
Unless you are on a
study like this one,
you cannot get cervical
cancer screening in Ghana
True 13.3% 9.1% 0.8†
False 72% 76.4%
Unsure 14.7% 14.6%
There are no stages to
cervical cancer; either
you have it or you don’t
True 29.7% 67.3% < 0.001†
False 51.4% 25.5%
Unsure 18.9% 7.3%
Cervical cancer is always
fatal, even if caught at
the early stages
True 19.2% 24.1% 0.7‡
False 65.8% 59.3%
Unsure 15.1% 16.7%
*percentages may not sum to 100 due to rounding
†Fisher’s exact test
‡Chi-squared test
~ multiple response item, presented as proportions of responses
-- p values not calculated; multiple response items
♦ denotes “expected knowledge item” – discussed in parent study information
and counselling
Question responses in bold denote correct response
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“The way through which we come to get it [HPV virus]
is if we and men about three or four have sex.” (40-
49yrs, HIV-positive, HPV-positive, cytology negative)
“Non-stigmatised” acquisition was expressed in the form
of simple statements that HPV is sexually transmitted.
Only one participant mentioned HIV-status affecting
vulnerability to infection:“I think when the doctor was
teaching us she made me understand that it can
attack everyone, but for those of us who specifically
have HIV, it is easy that we can get it [HPV virus]”
(30-39yrs, HIV-positive, HPV- and cytology-negative)
The most common misconception expressed about ac-
quisition was the effect of abortion (only expressed by
HIV-negative participants):“I was told that women who
cause abortions, those who have had cases of STDs,
and those who have a lot of sexual partners are all at
risk of getting infected.” (60-69yrs, HIV-negative, HPV-
positive, cytology-negative)
The early asymptomatic phase of cervical cancer made
it more difficult for women to define “what” cancer was;
for them cancer was something you could see or feel,
and identify by characteristic symptoms. This also
caused difficulty in identifying “what” HPV was, and in
reconciling its lack of symptoms with its harmful nature:
“At first, I thought cancer only affected the breast but
we went for a workshop and heard that it can also
affect the mouth of the womb, but that the cancer that
affects the mouth of the womb has no symptoms
because for the breast cancer you can see that your
breast has lump in it and look some style (does not
look normal) but they said for the cervical cancer it
will be there without showing so we should start doing
some test” (40-49yrs, HIV-positive, HPV- and cytology-
negative)
Only two (HIV-negative) women correctly expressed that
HPV is an infection that can lead to cancer if it persists.
When asked to describe the symptoms of cervical cancer
and HPV they were again described interchangeably. Sev-
eral women believed that HPV infection would cause vagi-
nal discharge was expressed. One woman described the
symptoms of advanced cervical cancer as:“vaginal discharge
with very bad smell, abdominal pains, a lot of
complications, loss of appetite, sores in the mouth, etc.
The cancer affects every part of the body.” (50-59yrs, HIV-
negative, HPV-positive, cytology-negative).
A strong sub-theme of “nature of the disease” was the
effect of HPV on men. Women queried whether it
would also cause disease in men, or whether there would
be any visible signs on men that they were infected with
HPV:“Does it mean that this HPV it can be on [infect]
males and it can be on females? But for the men when
they have it doesn’t it show on their bodies or it does it
not give them any problems?” (40-49yrs, HIV-positive,
HPV- and cytology-negative)
Some women expressed the belief that HPV would cause
visible symptoms in an infected man:“Me too I think
that if you are there with someone and he has it, you
will see that his skin is changing” (40-49yrs, HIV-
positive, HPV positive and cytology negative).
There were also feelings of frustration from participants
that men could engage in sexually “careless” behaviour
without fear of consequences as:“the disease will affect
you the woman” (60-69yrs, HIV-negative, HPV-
positive, cytology-negative)
Fig. 1 Proportion of women answering correctly which symptoms can be associated with cervical cancer, with breakdown by HIV-status among
131 women attending the Cape Coast Teaching Hospital, Ghana
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Condoms were mentioned frequently and emphatically
by participants as being important for protecting them-
selves and this was phrased in absolute terms:“I learnt
that when you have sex and you protect yourself you
will not be infected, usually through condom use.” (20-
29yrs, HIV-negative, HPV- and cytology-positive).
Modifying sexual behaviour by limiting one’s number of
sexual partners, or exhibiting sexual ‘restraint’ was also
expressed as an important factor in prevention, and was
commonly referred to as “being careful” or “taking car-
e”:“Eeeem … some people do not like condom so they will
have to, reduce the men they do sex with and all that”
(40-49yrs, HIV-positive, HPV- and cytology-negative)
“All we have to do is to take care of ourselves from this
disease. Like pulling ourselves away from some things that
when we do, it will not go and bring us this problem.” (30-
39yrs, HIV-positive, HPV- and cytology-negative)
Participants expressed feelings of powerlessness in pro-
tecting themselves from disease when discussing their
partners. “Fidelity” and “sexual negotiation” were pre-
dominant sub-themes. Male partners’ infidelity was
expected:“Because it is got from men, its prevention will
be difficult. A woman cannot advise her husband to
not have sex with other women.” (50-59yrs, HIV-
negative, HPV- and cytology-positive).
Women also believed that because in general men did
know about HPV or cervical cancer they would not be
taking any steps to reduce the risk of transmitting HPV
to their female partners, and that education of men
would be an important element in protecting women:“If
education could be given on radio and TV for me, I
believe it would help us.” (50-59yrs, HIV-negative,
HPV-positive, cytology-negative)
Experience of screening
Responses to the Likert-type questionnaire items are
presented in Table 3. Responses did not vary by HIV-
status. Among HIV negative versus HIV positive women,
a third of women (30.7% vrs. 35.0%) agreed that screen-
ing was embarrassing but most women did not find
screening painful (85.3% vrs. 85.0%).
The themes of “protection” and “testing” also emerged
from the FGD aspects focussed on experience of screen-
ing, but the theme “fear and anxiety” was additionally
constructed. Women were unanimous in their expres-
sion that learning about HPV and cervical cancer was
frightening; and for many this related to simultaneously
learning of the disease, and that they were at risk, for
the first time:
“Please, as for me it got me really scared, because me,
myself, I had not heard some. Before I knew it is only
breast that cancer affects, so me it got me very scared”
(40-49yrs, HIV-positive HPV-positive, cytology-
negative)
Other elements that generated anxiety were: the “not
knowing” that one could be infected with HPV due to
its asymptomatic nature; what this meant for one’s rela-
tionship to one’s partner (and the question of infidelity);
and media messages about cervical cancer:“What really
pains me a little about it, is that when you get it you
won’t get any symptoms that this is what is happening
to you” (40-49yrs, HIV-positive, HPV- and cytology-
negative)
“The way the doctor said it on TV made it sound
scary.” (40-49yrs, HIV-negative, HPV-positive, cytology-
negative)
When asked how they felt whilst waiting for their re-
sults, women commonly expressed that they found it dif-
ficult but receiving information and counselling from
health workers alleviated fears and anxiety as well as the
Table 3 Questionnaire responses on experience of screening,
Likert-type items by HIV-status (n = 131)
HIV-negative (%*)
n = 76
HIV-positive (%*)
n = 55
p value
“The screening
was embarrassing”
Disagree overall 50.7% 54.2% 0.4‡
Neutral 18.3% 10.2%
Agree overall 31.0% 35.6%
“The screening was painful”
Disagree overall 84.5% 85.0% 1.0†
Neutral 5.6% 6.7%
Agree overall 9.9% 8.3%
“I was worried about the
results of my screening”
Disagree overall 31.4% 30.0% 0.8‡
Neutral 30.0% 26.7%
Agree overall 38.6% 43.3%
“I was given enough
information about HPV,
cervical cancer, and the
screening test before
the screening”
Disagree overall 2.8% 1.7% 0.9†
Neutral 12.7% 10.0%
Agree overall 84.5% 88.3%
*percentages may not sum to 100 due to rounding
†Fisher’s exact test
‡Chi-squared test
Stuart et al. BMC Women's Health          (2019) 19:123 Page 7 of 11
fact that testing would help discover any problems at an
early stage:“I was scared, waiting for the result was very
scary. I could not even sleep.” (60-69yrs, HIV-negative,
HPV-positive, cytology-negative)
“It was scary at first but later I became relaxed. I also
was glad about the fact that I took the test because
then if there had been something it would be found
and stopped.” (40-49yrs, HIV-negative, HPV-positive,
cytology-negative).
When asked if they had sought information from other
sources between initial screening and follow up, under
half said “yes” (41.4,40.0%). The source of information
with the greatest proportion of responses was “other
healthcare professional” at 45% of responses (Table 4.)
Almost all women said they would have repeat cervical
screening if it was free, with a statistically-significant differ-
ence between groups (100, 91.4%; p = 0.02). Of those who
said they would have repeat cervical screening if it was free,
89.3% said they would also have it if there was a charge.
In FGDs women also talked about the cost of testing.
Some women were aware of cervical screening prior to
joining the parent-study but said they had not availed of
it due to cost. It was also mentioned that the govern-
ment should increase the availability of screening by re-
ducing the cost:
“The government should also try and reduce the cost
for us” (50-59yrs, HIV-negative, HPV-positive, cytology-
negative).
In FGDs, the view that screening was protective against
developing disease through both informing and educat-
ing women and detecting disease early was frequently
expressed:“If a test is done it would help prevent any
further damage the disease would have caused to the
womb if the result is positive. If it is negative, then you
will be educated on how to stay safe or protect
yourself.” (50-59yrs, HIV-negative, HPV-positive,
cytology-negative)
The sub-theme of “testing imperative” related to mul-
tiple expressions that testing was something that must
be done if the opportunity presents itself; and that other
women should seek testing. However, this was only
voiced by women who had had a positive HPV result:“-
Whether morning or afternoon, wherever they call you
for the test you will have to do it.” (40-49yrs, HIV-
positive, HPV-positive, cytology-negative)
“This should be of greater concern to all women so
that from time to time we can run the tests.” (40-49yrs,
HIV-negative, HPV-positive, cytology-negative)
Discussion
In this study of mixed HIV-status women who had under-
gone cervical screening in Cape Coast, Ghana, we found
good levels of knowledge of HPV, cervical cancer, and cer-
vical screening, with 85–100% of participants able to cor-
rectly identify major factual points (HPV is sexually
transmitted, HPV causes cervical cancer, cervical cancer
can be prevented). Despite lower overall education status
amongst HIV-positive women, there was no significant
difference in mean knowledge score between groups. Spe-
cific misconceptions and attitudes to these subjects were
highlighted through the FGDs, with stigmatising language
used around the acquisition of HPV. Women had mixed
experiences of the screening process, with around a third
(HIV-negative: 30.7%, HIV-positive: 35.0%) finding it
embarrassing, and a larger proportion (38.6% vrs. 43.3%)
experiencing anxiety around their results. This anxiety
Table 4 Questionnaire responses: information seeking and
impact of screening, by HIV-status
HIV-negative (%*)
N = 76
HIV-positive (%*)
N = 55
p values
Did you seek information
about HPV/cervical cancer/
cervical screening from
anywhere else between
having the initial testing
and coming back for
follow up?
Yes 41.4% 40.0% 0.9‡
If yes, where did you
look for information~
Friends/family 8.3% 12.5% –
Doctors 22.2% 16.6%
Other healthcare
professional
44.4% 45.8%
Internet 25.0% 25.0%
Would you have cervical
cancer screening again
if it was free?
Yes 100.0% 91.4% 0.02†
Would you have cervical
cancer screening again
if you had to pay for it?
Yes 90.3% 80.7% 0.1‡
“I have told other women
they should have cervical
cancer screening”
Yes 70.6% 70.2% 1.0‡
*percentages may not sum to 100 due to rounding
~multiple response item, presented as proportions of responses
†Fisher’s exact test
‡Chi-squared test
-- p values not calculated; multiple response items
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element was echoed in the FGDs, but the positive aspects
of screening and education provided by healthcare profes-
sionals were also highlighted.
Other studies in Ghana and SSA where women have
not had specific health education has found knowledge
of HPV, cervical cancer, and screening women to be
poor [9, 16, 35]. This implies that for our cohort know-
ledge was gained through the parent-study counselling,
but may have additionally been due to women being
motivated to seek information: indeed, 40% of partici-
pants from both HIV-status groups sought information
from other sources between initial screening and follow-
up. The increased exposure of HIV-positive women to
health education through regular HIV care may account
for differences in knowledge responses, and also explain
why lower levels of formal education in this group did
not have an effect on knowledge scores.
Specific misconceptions were apparent in the FGDs,
particularly in relation to the difference between HPV
infection and cervical cancer. Many women expressed
the belief that they were the same thing, and described
them interchangeably. Participants rarely expressed
knowledge of the latency period between HPV infection
and development of cancer, contrasting with a Zambian
study where this was frequently mentioned [36]. Overall,
misconceptions appeared to be fewer than those found
in other studies in SSA where vaginal hygiene practices,
contraceptive and tampon use, witchcraft, benign vaginal
infections, and “too much sex” were attributed causes of
cervical cancer [15, 37, 38]. Whether misconceptions
and knowledge gaps were due to the way in which study
counselling was delivered, the interpretation of know-
ledge received, or pre-existing ideas and cultural con-
cepts of disease is difficult to assess, but these findings
have implications for the design of future education
messages. Qualitative work in high-income populations
has shown that screening can generate confusion for
women with information from healthcare professionals,
information leaflets and the internet often not meeting
their needs [24, 39–41].
Stigma attached to the sexual transmission of HPV is a
major theme in qualitative studies in many countries, and
women usually frame this in the context of self-blame and
shame for having “given themselves cancer” [23, 41, 42].
Women in our study expressed “stigmatised” statements
that HPV infection was due to sexual promiscuity and a
lack of sexual self-control; this was especially prominent
amongst HIV-positive FGD participants. This may high-
light a different health counselling need in women living
with HIV with regards to cervical screening.
Women were clear that condoms offered protection
(82.7, 94.6%), and HIV-positive participants seemed to
have adopted the HIV prevention message “use a con-
dom every time you have sex” as applicable to HPV.
A third of women found screening embarrassing, as is
commonly reported [11, 31, 43]. Self-sampling is sug-
gested as a potential means of managing this barrier
[31]. Less than 10% of women found screening painful;
an aspect that could be shared with unscreened women,
as fear of pain can be a reason for screening-avoidance
[43–45]. Women expressed other causes of fear and anx-
iety such as “scary” public health campaigns, finding out
about HPV and cervical cancer for the first time, and
waiting for their results. This is consistent with research
in high-income countries where HPV-DNA testing and
cervical cancer screening have been shown to generate
anxiety and distress [46–48]. Having one’s information
needs met was the same protective factor against
screening-anxiety mentioned by these women as women
in high-income-settings [24, 40, 49]. A UK study found
that women with poorer access to information and of
lower educational status reported more anxiety about
HPV-DNA testing results, which echoes our finding that
women with less education were more likely to worry
about test results [24].
Over 90% of women in both groups understood that
cervical cancer is preventable (90.8% vrs. 94.6%) among
HIV negative compared with HIV positive women, and
that screening should be done even if asymptomatic
(94.7% vrs. 94.6%). Women also expressed that screening
allows early detection and treatment of problems. This
contrasts with a qualitative study in Ghana, where women
strongly expressed that screening was only necessary if
one had symptoms, again showing the effectiveness of
study counselling [50].
Cost is a reported barrier to screening in other studies in
SSA [15, 43], and this was also evident in our study. Some
women had not had previous screening due to cost, and a
number indicated that they would have screening again
only if deemed medically “necessary” and at a lower price.
Strengths and limitations
This study is the first in West Africa that examines the
knowledge and experiences of women who have under-
gone cervical screening with two screening methods
(HPV-DNA testing and cervical cytology). It provides a
unique perspective on the impact of health education
from screening, and psychological experiences of screen-
ing in women of mixed HIV-status. Both the question-
naire and scoring system used were developed
specifically for this study and were unvalidated. There
was no pre-existing validated tool suitable for use with
this particular population.
Furthermore, we did not assess knowledge levels be-
fore participation in the study and cannot assume that
knowledge “gains” were made, although it seems likely
based on participant statements during the FGDs and
comparison with existing research in similar settings. In
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addition, since these women had undergone screening
and received some education from healthcare workers, it
is acknowledged that they do not necessarily reflect the
general population hence their knowledge may not rep-
resent women across Ghana and differences between
HIV-positive and negative women needs to be explored
further.
Ideally, questionnaire responses would have been used
to develop the FGD topic-guide, and more FGDs should
have been conducted to verify if saturation was achieved.
However, this was not possible due to time constraints.
As a result, there were aspects of each study component
that were not explored in the other, causing some loss of
cohesiveness.
Conclusions
This study showed that whilst knowledge of HPV and cer-
vical cancer in women who had participated in a screening
study was good, specific misconceptions still existed. A
standardised education tool explaining cervical screening
and specifically HPV-DNA testing in Ghana may be
needed, which should be made accessible to women with
low formal education, and may take into account the differ-
ent needs of HIV-positive women. Public health messaging
should take into account the issues of fear and economic
barriers to accessing services. Further research into the psy-
chological effects of cervical cancer screening on women in
Ghana should be undertaken, in order to strengthen the
knowledge base to improve screening, especially as HPV-
DNA testing becomes more widely used.
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